Peptide LexiconAll compounds

Vesugen (Lys-Glu-Asp): The Three-Amino-Acid 'Vascular Bioregulator' — What It Is and What Six PubMed Records Show

Vesugen is the synthetic tripeptide Lys-Glu-Asp (KED), a short 'bioregulator' from the St Petersburg programme, sold for blood vessels and ageing. PubMed holds six records naming it, from 2008 to 2015: five cell or animal studies and one 32-person report with no control group described. No trial is registered.

Not approved anywhere this entry foundNo registered trialSingle-programme evidence base

Caroline S · Published 2026-11-13

Length

3 amino acids — C15H26N4O8, molecular weight 390.39 (PubChem CID 87571363)

Sequence

KED (Lys-Glu-Asp)

Origin

Synthetic; the vessel-labelled tripeptide of the St Petersburg short-peptide series associated with V. Khavinson

Last reviewed

2026-11-13

What is it good for?

Sellers present it as a bioregulator for blood vessels and ageing. Nothing has been shown in a controlled human trial. The six PubMed records that name it are five laboratory studies — cultured cells, tissue cultures and a low-oxygen model — and one Russian-language report on 32 patients that describes no control group and itself reports a pro-oxidant effect and a fall in blood stem-cell markers.

Illustration: An open dark green notebook with a white page and a copper pen on a white desk.
Illustration

What it is

Vesugen is three amino acids in a row: lysine, glutamic acid, aspartic acid. PubChem holds the structure under the name Lys-Glu-Asp (CID 87571363), with the formula C15H26N4O8 and a molecular weight of 390.39. Searching PubChem for the word "vesugen" returns nothing; the trade name and the chemical record are not linked there (2026-11-13).

The sequence is confirmed by the originating group's own paper, which writes "vesugen (Lys-Glu-Asp)" (Khavinson et al. 2012, PMID 22808515). Add a proline and the chain becomes Prostamax, Lys-Glu-Asp-Pro, the series' prostate peptide. A different four-letter member, Cortagen (Ala-Glu-Asp-Pro), shares Prostamax's last three residues and is the series' brain-cortex peptide. It is the vessel entry in the same St Petersburg peptide bioregulator series, associated with V. Khavinson, that produced epitalon, the dipeptide Vilon and the brain-targeted tripeptide Pinealon. Vesugen is Vilon's two amino acids plus one more.

What the research shows

A PubMed search on 2026-11-13 for "vesugen" in titles and abstracts returned 6 records, published between 2008 and 2015. This entry read all six abstracts.

Year Kind of study What the abstract reports PMID
2008 Test-tube and cell models With three related peptides: no direct antioxidant activity; limited lipid peroxidation; raised reactive oxygen species inside cells 18546826
2008 Low-oxygen (hypobaric hypoxia) model Four peptides showed anti-hypoxic properties; pinealon "the most pronounced" 18546825
2011 Pineal tissue culture Vesugen "had no effect on differentiation capacity" of immune cells but enhanced their proliferation 22803057
2012 Human prostate fibroblasts in culture Raised two differentiation markers in aged cultures 22808515
2014 Blood-vessel lining cells in culture; computer model Raised Ki-67, a marker of cell division; docking model of the peptide against the gene's promoter 25051766
2015 32 patients aged 41–83 "Significant anabolic effect" and slower ageing by biological-age indicators; also pro-oxidant activity and fewer CD34-positive cells 26390612

Four of the six are in Russian, in the programme's own gerontology journal.

The one human report, read closely

The 2015 paper is the whole of the indexed human evidence. Its abstract describes 32 people with several chronic illnesses and a brain disorder in remission, given vesugen or pinealon.

Three things stand out. The abstract mentions no control group, no placebo and no randomisation. Its own head-count does not add up: "32 people (18 men, 12 women)" is 30. And its findings point both ways — alongside an "anabolic effect", the authors report pro-oxidant activity and a decrease in CD34-positive cells that they describe as "significant inhibition of hemopoiesis", meaning blood-cell formation. The abstract nonetheless ends by recommending the peptides for geriatric practice; that is the authors' recommendation, and this library reports it without endorsing it.

The 2014 cell paper refers to a "vasoprotective effect of peptide vesugen revealed previously in elder people." No PubMed record under the name contains that earlier study, and this entry could not find it.

What is not established

  • A vessel benefit against a comparison group. The 32-patient report had none described, so its "slower ageing" reading cannot be separated from time, other treatment or chance.
  • What the two warning signals mean. Pro-oxidant activity and fewer CD34-positive cells were reported in the same patients and then left there; no later indexed paper returns to them.
  • The "earlier study in elder people". The 2014 paper cites a vasoprotective result in older people that no PubMed record under the name contains.
  • Whether KED reaches the vessel wall. The endothelial-cell result came from peptide added straight to a culture dish; no abstract tracks it in blood.
  • Work from a second group. No paper from outside the programme and its collaborators is indexed; four of the six appeared in its own journal.

Where it stands

  • Regulatory status: unapproved in every record checked; PubChem knows the molecule only as Lys-Glu-Asp, not by the trade name.
  • Where readers meet it: vessel and circulation bioregulator listings, alone or blended. Those products are not assessed here.
  • Size of the record (2026-11-13): six PubMed papers from 2008 to 2015, one of them on people; ClinicalTrials.gov returns nothing for the name.

The same programme's heart-labelled peptide is described in the cardiogen entry, and its cartilage-labelled one in the cartalax entry. The gland extract these short peptides descend from is covered under thymalin. For how the claims made for longevity peptides compare with their human evidence, see the longevity overview.

What the research shows

Supports blood-vessel lining cells as they age

Khavinson et al. 2014 (PMID 25051766): raised the proliferation marker Ki-67 in cultured vascular endothelial cells; binding to the gene's promoter was a computer docking model

Restores markers of cell differentiation in ageing cultures

Khavinson et al. 2012 (PMID 22808515): CXCL12 and a second marker in late-passage human prostate fibroblasts — cell culture

Slows ageing in patients

Meshchaninov et al. 2015 (PMID 26390612): 32 patients aged 41–83; no control group or randomisation in the abstract; reports 'prooxidant activity' and 'significant inhibition of hemopoiesis' alongside its favourable findings

Protects against low oxygen

Kozina 2008 (PMID 18546825): hypobaric hypoxia model, four peptides compared; pinealon, not vesugen, had the most pronounced effect

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

Approved as a medicine

No approval found. No indexed paper reports one, and the name returns no compound record in PubChem; the structure is there as Lys-Glu-Asp (2026-11-13).

Trials

ClinicalTrials.gov: 0 studies for 'vesugen' (2026-11-13; a control search on the same day returned 836).

Published record

PubMed: 6 records with 'vesugen' in the title or abstract, 2008–2015; 0 tagged as randomised controlled trials (2026-11-13).

Frequently asked questions

What is Vesugen?

A synthetic tripeptide — lysine, glutamic acid and aspartic acid joined in that order, written Lys-Glu-Asp or KED. It comes from the St Petersburg peptide bioregulator programme.

What is Vesugen said to be good for?

Sellers present it for blood vessels and healthy ageing. The published support is laboratory work on cells and tissues plus one small patient report; no controlled human trial exists in PubMed or ClinicalTrials.gov.

Has Vesugen been tested in humans?

PubMed names one study: 32 patients aged 41 to 83 given vesugen or pinealon, published in Russian in 2015. Its abstract describes no control group, and reports a pro-oxidant effect and a fall in blood stem-cell markers as well as favourable changes.

Is Vesugen the same as Vilon?

No. Vilon is the dipeptide Lys-Glu. Vesugen has one more amino acid, aspartic acid, on the end: Lys-Glu-Asp.

Is Vesugen approved?

No approval turned up, and no indexed paper claims one. Vesugen reaches buyers as a research peptide or as one component of vessel-themed bioregulator blends; this library describes the compound, not those products.

Does Vesugen act on genes?

That is the programme's hypothesis. The 2014 paper proposing it used a computer docking model of the peptide against a stretch of DNA; it has not been shown in people.